Your browser is no longer supported. Please, upgrade your browser.
CEL-SCI Corporation
Index- P/E- EPS (ttm)-0.88 Insider Own4.10% Shs Outstand40.53M Perf Week4.39%
Market Cap840.28M Forward P/E21.27 EPS next Y1.05 Insider Trans-1.12% Shs Float38.74M Perf Month35.58%
Income-32.90M PEG- EPS next Q-0.19 Inst Own31.70% Short Float25.81% Perf Quarter-5.18%
Sales0.50M P/S1680.56 EPS this Y-16.00% Inst Trans0.83% Short Ratio10.27 Perf Half Y84.70%
Book/sh0.75 P/B29.77 EPS next Y- ROA-77.20% Target Price19.00 Perf Year44.91%
Cash/sh0.58 P/C38.37 EPS next 5Y- ROE-157.60% 52W Range10.76 - 40.91 Perf YTD91.51%
Dividend- P/FCF- EPS past 5Y39.90% ROI-89.50% 52W High-45.42% Beta2.26
Dividend %- Quick Ratio3.10 Sales past 5Y-3.20% Gross Margin- 52W Low107.53% ATR2.09
Employees43 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)54.87 Volatility9.08% 10.84%
OptionableYes Debt/Eq0.43 EPS Q/Q-31.60% Profit Margin- Rel Volume0.58 Prev Close20.61
ShortableYes LT Debt/Eq0.40 Earnings- Payout- Avg Volume973.34K Price22.33
Recom2.00 SMA201.76% SMA5015.85% SMA20042.41% Volume560,971 Change8.35%
Jan-13-20Initiated H.C. Wainwright Buy $18
Mar-02-15Initiated Dawson James Buy $3
Apr-28-21 03:26PM  
Apr-15-21 03:41PM  
Apr-07-21 03:15AM  
Mar-09-21 06:17AM  
Mar-01-21 05:15AM  
Feb-16-21 09:00AM  
Jan-29-21 06:27AM  
Jan-28-21 06:21PM  
Jan-27-21 04:07PM  
Jan-11-21 05:21AM  
Jan-08-21 08:30AM  
Jan-07-21 01:08AM  
Jan-04-21 09:15AM  
Dec-30-20 08:00AM  
Dec-14-20 08:30AM  
Dec-11-20 11:29AM  
Dec-08-20 06:44PM  
Dec-07-20 09:15AM  
Dec-02-20 11:16AM  
Dec-01-20 09:00AM  
Oct-14-20 07:19AM  
Sep-18-20 09:00AM  
Sep-15-20 09:15AM  
Sep-11-20 09:00AM  
Sep-01-20 04:34PM  
Aug-31-20 09:00AM  
Aug-25-20 06:13AM  
Aug-11-20 08:30AM  
Aug-05-20 09:00AM  
Jul-24-20 08:30AM  
Jul-16-20 09:38AM  
Jun-30-20 08:30AM  
Jun-24-20 10:00AM  
Jun-10-20 01:30PM  
May-28-20 01:07PM  
May-11-20 08:00AM  
May-08-20 06:20AM  
May-04-20 07:15AM  
Apr-23-20 09:15AM  
Apr-08-20 08:00AM  
Mar-30-20 04:05PM  
Mar-26-20 11:05AM  
Mar-24-20 09:25AM  
Mar-23-20 09:46PM  
Mar-10-20 12:00PM  
Mar-09-20 07:55AM  
Feb-27-20 12:44PM  
Feb-26-20 03:19PM  
Feb-10-20 08:00AM  
Feb-06-20 09:00AM  
Jan-10-20 08:30AM  
Jan-07-20 02:40PM  
Dec-27-19 11:15AM  
Dec-26-19 09:59AM  
Dec-24-19 07:16AM  
Dec-23-19 04:04PM  
Dec-20-19 03:28PM  
Dec-16-19 04:15PM  
Dec-06-19 09:00AM  
Oct-29-19 07:00AM  
Oct-24-19 09:00AM  
Oct-16-19 07:30PM  
Oct-15-19 08:30AM  
Sep-25-19 11:35AM  
Sep-04-19 12:14PM  
Aug-14-19 04:20PM  
Jul-23-19 09:30AM  
Jul-08-19 09:00AM  
Jun-23-19 09:00AM  
Jun-19-19 10:30AM  
Jun-11-19 04:35PM  
Jun-10-19 09:00AM  
Jun-03-19 09:00AM  
May-29-19 01:00PM  
May-14-19 04:33PM  
May-13-19 09:00AM  
May-08-19 08:00AM  
Apr-30-19 09:00AM  
Mar-29-19 09:00AM  
Mar-26-19 06:16PM  
Mar-25-19 08:12AM  
Mar-07-19 11:00AM  
Mar-04-19 08:00AM  
Mar-01-19 11:45AM  
Feb-14-19 04:27PM  
Feb-07-19 09:00AM  
Feb-04-19 10:00AM  
Feb-01-19 11:30AM  
Jan-23-19 09:20AM  
Jan-15-19 08:00AM  
Dec-20-18 09:00AM  
Nov-23-18 08:55AM  
Oct-23-18 08:30AM  
Oct-16-18 10:55AM  
Oct-01-18 08:30AM  
Sep-28-18 08:00AM  
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CIPRIANO JOHNSenior Vice PresidentApr 22Sale24.3810,000243,79363,108Apr 23 05:16 PM
YOUNG PETER RDirectorDec 11Buy14.241001,42425,914Dec 16 09:16 AM
BAILLAVOINE BRUNO JEAN-MARIEDirectorNov 18Buy11.778009,4164,723Nov 18 10:45 AM
Watson Robert EugeneDirectorNov 18Buy11.778009,4163,181Nov 18 09:59 AM
YOUNG PETER RDirectorNov 17Buy11.688009,34325,814Nov 18 11:10 AM
CIPRIANO JOHNSenior Vice PresidentNov 13Sale12.7310,000127,29073,108Nov 16 04:49 PM
YOUNG PETER RDirectorNov 04Buy11.342,00022,67025,014Nov 06 04:26 PM
YOUNG PETER RDirectorNov 04Buy11.391,00011,39023,014Nov 06 04:26 PM